VINEETLABVineet Laboratories Limited
Chemicals · Chemicals · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was incorporated in 2016 and is based in Hyderabad, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
Why avoid
- • Risk gate: safety score is only 25/100 — volatility, drawdown or liquidity is too poor for a buy call, whatever the chart says
- • ROE: 3.7%
- • ROCE: -34.3%
- • MACD: bearish
- • 3-month return: -3.0%
⚖️ 1 bullish pattern setup is currently active on this stock. Pattern setup-quality percentages measure how cleanly a chart formation developed — they are not an endorsement of the company. Short-term traders may still trade those setups with strict stops; the AVOID verdict reflects the overall risk/fundamental profile for holding.
Bull case
- • Revenue growth: 22.6% YoY
- • Profit growth: 105.5% YoY
- • PEG ratio: 0.35
- • Price vs EMA21: above
Bear case
- • ROE: 3.7%
- • ROCE: -34.3%
- • MACD: bearish
- • 3-month return: -3.0%
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • ROE: 3.7%
- • ROCE: -34.3%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹2.17). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.